A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

Prior treatment

• Untreated or progressive CNS disease unless previously treated and stable.
• Prior CD70-targeting therapy, including CAR T.
• ASCT or CAR T ≤12 weeks before enrollment; prior organ or allogeneic transplant.
• Unresolved ≥Grade 2 toxicity from prior therapy (with exceptions).

Other illness

• Other active invasive malignancy within 2 years (except certain low-risk cancers).
• Primary immunodeficiency or active autoimmune disease requiring immunosuppression.
• Active HBV, HCV, HIV, or other chronic infections requiring systemic therapy.

Other

• Pregnancy, breastfeeding, or unwillingness to use effective contraception.
  • Other protocol-defined Inclusion/Exclusion Criteria may apply.

• Age ≥18 years.
• ECOG performance status of 0 or 1.
• Histologically confirmed:
  • Clear cell renal cell carcinoma (ccRCC).
  • Diffuse large B-cell lymphoma (DLBCL, NOS).
  • High-grade B-cell lymphoma (HGBCL).
  • Peripheral T-cell lymphoma (PTCL, incl. NOS and ALCL).
  • Cutaneous T-cell lymphoma (CTCL, incl. MF or SS ≥Stage IIB with B0/B1 blood involvement).
• Disease progression, relapse, or refractory to prior therapy:
  • ccRCC: ≥1 prior line incl. ICI + TKI.
  • DLBCL/HGBCL: ≥2 prior lines incl. immunochemotherapy and salvage.
  • PTCL/CTCL: ≥1 prior systemic therapy.
• Measurable disease by RECIST v1.1 (ccRCC), Lugano 2014 (lymphomas), or ISCL/USCLC/EORTC (CTCL).
• Tumor tissue available for central testing.